For nearly four decades, mention of the Ebola virus has evoked death and terror, yet a simple factor — money — has stood in the way of erasing the curse, experts say.
Despite its evil reputation, Ebola breaks out only rarely in brief if murderous spurts in impoverished African countries.
That tiny — and poor — market means that the disease has been a very low priority for Big Pharma, given the hundreds of millions of dollars it can take to devise a new drug or vaccine.
Photo: AFP
Today, after years of low-key progress with the Pentagon as its main funder, the search for vaccines and drugs for Ebola has been thrown into higher gear and — for now — the profit factor has been put to one side.
“Until this west African epidemic, Ebola was not a public health problem and [was] a really rare disease,” says Peter Piot, director of the London School of Hygiene and Tropical Medicine, who codiscovered the Ebola virus in 1976.
“There was very little interest in all quarters, not just pharma,” Piot said in an e-mail. “Things have changed now, and two major companies are investing in a vaccine — GSK [GlaxoSmithKline] and [Johnson & Johnson subsidiary] Janssen.”
Sylvain Baize, in charge of the Viral Hemorrhagic Fevers Reference Center at France’s Pasteur Institute, said Ebola had claimed fewer than 2,000 lives in almost 40 years, a minute toll compared with other diseases.
“If these 2,000 deaths had occurred in industrialized countries, things may have been different, but it was 2,000 dead in the middle of Africa, so nobody cared very much,” Baize said sardonically.
Ebola’s extraordinary lethality was another reason that it never became a top target for research, he said.
“It has to be confined in a top-security ‘P4’ laboratory, of which there are very few in the world, so there are not many people who in fact can work on it,” Baize said.
The recent shakeup has been spurred by an epidemic in four west African countries — Guinea, Liberia, Nigeria and Sierra Leone — that has killed more than 2,400 people, about half of the confirmed infections. The outbreak has caused social dislocation and economic disruption, while breeding fears in neighboring countries and in Europe of the disease’s potential to spread.
The two treatments and two vaccines most advanced in the research pipeline are still at the very earliest testing stages to see whether they are safe — and if they work.
On Aug. 12, the WHO gave the green light to using experimental drugs for Ebola treatment, saying it would be ethical given the extent of the current crisis and because no cure or vaccine so far exists. Human trials typically take several years under an exhaustive, three-phase vetting procedure.
On Sept. 5, the WHO voiced hopes that a vaccine would be available in November for frontline health workers.
If this fast-tracking process yields results, it raises the next question: Who will pay to manufacture the drug and distribute it?
“Ebola is a classic orphan disease,” said Annette Rid, a doctor of bioethics at King’s College London, adding that public funds, charities and institutional donors would have to stump up the seed money.
“Once it is established that a therapy or vaccine is effective, stockpiles need to be established in those African countries where Ebola is likely to re-emerge,” Piot said. “This can be funded by the international community and done under the aegis of the WHO.”
US National Institute of Allergy and Infectious Diseases director Anthony Fauci said he was increasingly optimistic that Big Pharma would play a role, given the scale of the crisis.
“I think there was previously no incentive, but now that everyone sees that it is a big problem, we are getting more and more companies involved,” he said.
Seth Berkley, head of the GAVI Alliance, a public-private partnership designed to bring vaccines to poor countries, said a panoply of tools existed for harnessing the profit motive.
“You can directly finance the vaccine technology transfer, you can incentivize companies by funding them directly, you can create an advanced market commitment with supplemental funds to try to make it a good deal for business, you can create a long-term plan for buying the vaccines as an incentive,” he said. “There is a range of mechanisms there and it could be done rather quickly.”
BUSINESS UPDATE: The iPhone assembler said operations outlook is expected to show quarter-on-quarter and year-on-year growth for the second quarter Hon Hai Precision Industry Co (鴻海精密) yesterday reported strong growth in sales last month, potentially raising expectations for iPhone sales while artificial intelligence (AI)-related business booms. The company, which assembles the majority of Apple Inc’s smartphones, reported a 19.03 percent rise in monthly sales to NT$510.9 billion (US$15.78 billion), from NT$429.22 billion in the same period last year. On a monthly basis, sales rose 14.16 percent, it said. The company in a statement said that last month’s revenue was a record-breaking April performance. Hon Hai, known also as Foxconn Technology Group (富士康科技集團), assembles most iPhones, but the company is diversifying its business to
ARTIFICIAL INTELLIGENCE: The chipmaker last month raised its capital spending by 28 percent for this year to NT$32 billion from a previous estimate of NT$25 billion Contract chipmaker Powerchip Semiconductor Manufacturing Corp (力積電子) yesterday launched a new 12-inch fab, tapping into advanced chip-on-wafer-on-substrate (CoWoS) packaging technology to support rising demand for artificial intelligence (AI) devices. Powerchip is to offer interposers, one of three parts in CoWoS packaging technology, with shipments scheduled for the second half of this year, Powerchip chairman Frank Huang (黃崇仁) told reporters on the sidelines of a fab inauguration ceremony in the Tongluo Science Park (銅鑼科學園區) in Miaoli County yesterday. “We are working with customers to supply CoWoS-related business, utilizing part of this new fab’s capacity,” Huang said, adding that Powerchip intended to bridge
Qualcomm Inc, the world’s biggest seller of smartphone processors, gave an upbeat forecast for sales and profit in the current period, suggesting demand for handsets is increasing after a two-year slump. Revenue in the three months ended in June will be US$8.8 billion to US$9.6 billion, the company said in a statement Wednesday. Excluding certain items, earnings will be US$2.15 to US$2.35 a share. Analysts had projected sales of US$9.08 billion and earnings of US$2.16 a share. The outlook signals that the smartphone market has begun to bounce back, tracking with Qualcomm’s forecast that demand would gradually recover this year. The San
Clambering hand-over-hand, sweat dripping into his eyes, a durian laborer expertly slices a cumbersome fruit from a tree before tossing it down to land with a soft thump in his colleague’s waiting arms about 15m below. Among Thailand’s most famous and lucrative exports, the pungent “king of fruits” is as distinctive in its smell as its spiky green-brown carapace, and has been farmed in the kingdom for hundreds of years. However, a vicious heat wave engulfing Southeast Asia has resulted in smaller yields and spiraling costs, with growers and sellers increasingly panicked as global warming damages the industry. “This year is a crisis,”